Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR2 |
Variant | N550H |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR2 N550H (corresponds to N549H in the canonical isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550H results in increased Fgfr2 kinase activity, as well as increased Fgfr2 phosphorylation and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597). |
Associated Drug Resistance | Y |
Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 N550H |
Transcript | NM_022970 |
gDNA | chr10:g.121498522T>G |
cDNA | c.1648A>C |
Protein | p.N550H |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_022970.3 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919.1 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144919 | chr10:g.121488065T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144913 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_022970 | chr10:g.121498522T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
NM_001144914 | chr10:g.121487993T>G | c.1648A>C | p.N550H | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 fusion FGFR2 N550H | intrahepatic cholangiocarcinoma | decreased response | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923). | 31109923 |
FGFR2 fusion FGFR2 N550H | intrahepatic cholangiocarcinoma | decreased response | Debio 1347 | Preclinical - Cell culture | Actionable | In a preclinical study, Debio 1347 treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H had weakened sensitivity, as demonstrated by cell viability and downstream signaling assays (PMID: 31109923). | 31109923 |
FGFR2 fusion FGFR2 N550H | intrahepatic cholangiocarcinoma | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) treatment of intrahepatic cholangiocarcinoma cells with an FGFR2 fusion in context with FGFR2 N550H were sensitive to treatment as demonstrated by decreased cell viability and decreased activation of downstream signaling (PMID: 31109923). | 31109923 |